By Will Boggs, MD NEW YORK (Reuters Health) – Improved survival among women with stage I or II endometrial cancer who undergo radiotherapy and lymphadenectomy may be attributable…
By Will Boggs, MD NEW YORK (Reuters Health) – Some patients with gastrointestinal stromal tumors (GIST) may benefit from resuming imatinib even after a previous failure of imatinib…
NEW YORK (Reuters Health) – A review of the literature has shown that the most important harms from cancer screening are often not quantified in screening trials. “Healthcare…
NEW YORK (Reuters Health) – Ten-year follow-up data from two UK trials confirm that a lower total dose of radiotherapy delivered in fewer, larger fractions is at least…
NEW YORK (Reuters Health) – The combination of pomalidomide and low-dose dexamethasone improves survival in patients with advanced multiple myeloma more than does treatment with high-dose dexamethasone alone,…
NEW YORK (Reuters Health) – Australian and Canadian researchers have shown in lab experiments that L-type amino acid transporters (LATS) are crucial to the growth and proliferation of…
NEW YORK (Reuters Health) – In smokers and former smokers, annual lung cancer screening with low-dose (LD) CT scans should not be discontinued after a negative result, according…
NEW YORK (Reuters Health) – Elderly patients with unresected stage III non-small-cell lung cancer (NSCLC) who are not candidates for chemoradiotherapy benefit from radiation therapy (RT) alone, according…
NEW YORK (Reuters Health) – After resection of pancreatic adenocarcinoma, chemotherapy with fluorouracil or gemcitabine reduces mortality by about a third, Taiwanese researchers have shown. On the other…
NEW YORK (Reuters Health) – Among several different DNA-based quantitative polymerase chain reaction (qPCR) assays for detecting a critical JAK2 mutation in myeloproliferative neoplasms, one stands out as…
